Ambulatory EEG in Patients with Early Onset Alzheimer’s Disease from the LEADS TRIAL
Abstract number :
3.174
Submission category :
3. Neurophysiology / 3C. Other Clinical EEG
Year :
2022
Submission ID :
2205161
Source :
www.aesnet.org
Presentation date :
12/5/2022 12:00:00 PM
Published date :
Nov 22, 2022, 05:28 AM
Authors :
Sofia Sanchez Boluarte, MD – Instituto Nacional de Ciencias Neurologicas; William Tatum, MD – Mayo Clinic; Alana Campbell, MD – Mayo Clinic; Neill Graff-Radford, MD – Mayo Clinic
Rationale: Alzheimer's disease is a main cause of cognitive impairment, there is growing evidence of epileptic seizures in this population. Identifying seizures could imply changes in the management and in the natural course of this entity. The objective was to characterize the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram (aEEG).
Methods: We recruited subjects from the LEADS trial, 40 to 64 years of age, with a diagnosis of EOAD. They underwent a 48-computer assisted ambulatory electroencephalogram (aEEG) with a portable 16 channel.
Results: Five participants were included, 3 (60%) were female, with a mean of age of 61 (range, 56-64). Three (60%) aEEG had abnormal results, one had moderately severe degree of diffuse slowing of the background activity, other had mild to moderate degree of focal slowing involving the left temporal head region, and one had spike epileptiform discharges in the temporal lobes. Subclinical seizures were not detected during the recording sessions.
Conclusions: Our series in patients of the LEADS trial showed that the majority of the participants had abnormal aEEGs of 48 hours, suggesting variability of EOAD, from mild to severe non-epileptic to epileptiform discharges.
Funding: Mayo Clinic
Neurophysiology